key: cord-0788499-7w3a2dpt
authors: Pino, Maria Simona; Cheli, Simone; Perna, Marco; Fabbroni, Valentina; Giordano, Clara; Martella, Francesca; Lanini, Fabio; Ribecco, Angela Stefania; Scoccianti, Silvia; Bacci, Carlotta; Baldazzi, Valentina; Bertolini, Ilaria; Di Leonardo, Greta; Fulignati, Chiara; Grifoni, Raffaella; Molinara, Elena; Rangan, Sheila; Tassi, Renato; Furlan, Federica; Goldzweig, Gil; Bassetti, Andrea; Fioretto, Luisa
title: The National COVID-19 Vaccination Campaign Targeting the Extremely Vulnerable: the Florence Medical Oncology Unit Experience in Patients with Cancer
date: 2022-04-20
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2022.04.008
sha: 0278a1c4efc1ce5a368f08bb6a376b70ed44c991
doc_id: 788499
cord_uid: 7w3a2dpt

BACKGROUND: International and national oncology societies had released recommendations in favor of COVID-19 vaccination in cancer patients. In the context of the national vaccination campaign targeting the so called extremely vulnerable, we aimed to assess the safety and efficacy of the mRNA vaccines in a cohort of 623 patients. METHODS: Between March 26(th), and April 04(th), 2021, the Pfizer and BioNTech BNT162b2 mRNA and the Moderna mRNA-1273 vaccines were given as a two-dose prime-boost regimen. Starting on September 25(th) 2021 a third dose was offered to patients in whom a suboptimal immunogenicity with COVID-19 vaccination could be expected. Safety assessments was performed by phone call 7 days after each dose. Electronic health records were accessed to review demographic information, disease history, treatment detail, and outcome events of participants patients’. FINDINGS: No toxicities were reported in 63.7%, 54%, and, in 48.7% patients with cancer after each dose. Mild-to-moderate pain at the injection site was the most commonly adverse event. After the second dose, 46% of the 610 patients reported toxicity, with more systemic side-effects observed. Fever was reported in 45% of patients, with a temperature ≥38 °C in 21.4% of them. Of the 335 patients receiving a third vaccine dose, 51% reported toxicity, with 13% of patients reporting more than one effect. Logistic regression analysis reported mixed results, with limited variables or categories reporting a significant odd ratio. The type of vaccine reported a significant value at first dose (OR= 0.12; CI 0.52, 0.26; p= 0.00). Thirty-four cases of COVID-19 infection were reported with only one patient requiring a short-term hospitalization for monitoring. INTERPRETATION: The safety profile of the mRNA vaccines does not raise any specific concerns and support prioritisation of vaccination for cancer patients.

About two year after its onset, the SARS-CoV-2 pandemic has recorded 326.286.532 cases and 5.536.789 deaths worldwide 1 . Among the worst-hit countries, Italy developed its strategic plan for anti-SARS-CoV-2/COVID-19 vaccination well in advance and identified priority target groups for COVID-19 vaccines at different stages of supply availability 2 . The risk of infection, severe illness, and death due to COVID-19 are higher among patients with cancer compared to the general population [3] [4] [5] [6] [7] [8] [9] [10] [11] . On March, 2021, the Italian governments and authorities at National and Regional levels have prioritized COVID-19 vaccinations for cancer patients.

Although vaccinations in cancer patients undergoing active treatment may be less effective in preventing infections, vaccination practice is generally able to decreased duration and severity of the infection and potentially to improve morbidity and mortality even in potentially compromised patients 12, 13 . Moreover, as immunocompromised individuals might be a source of prolonged viral shedding and could contribute to the onset of virus variants, the vaccination of patients with cancer is a key part of the public health management. On this basis, and despite most of the registry trials of COVID-19 vaccines excluded patients with active malignancies, or those receiving systemic anticancer therapies, international and national oncology societies had released recommendations in favor of COVID-19 vaccination, regardless of treatment type or underlying cancer [14] [15] [16] .

Furthermore, based on the few studies that have specifically reported on vaccine safety outcomes in patients with cancer receiving treatment, no safety concerns have been reported so far 17-20 .

In the context of the national vaccination campaign targeting the so called extremely vulnerable, we aimed to address the safety and efficacy of the mRNA vaccines in a cohort of patients with solid tumors.

According to the National Italian Cancer Vaccination Strategy for the extremely vulnerable individuals, cancer patients on systemic antitumor treatment, or whose treatment has been completed in the last 6 months, or having an active advanced disease, were considered eligible for vaccination regardless of disease stage, performance status, or life expectancy 2 . Between March 26 th , 2021 and April 04 th , 2021, vaccination was offered to patients followed at the Medical Oncology Unit in Florence at Santa Maria Annunziata, Serristori and Borgo San Lorenzo Hospitals.

Adherence to SARS-CoV-2 vaccine and reasons of refusal were collected. The Pfizer and BioNTech BNT162b2 mRNA and the Moderna mRNA-1273 vaccines were given as a two-dose prime-boost regimen 21 days (for BNT162b2) or 28 days (for mRNA-1273) apart 4, 21, 22 . Patients who were previously infected with SARS-CoV-2 were excluded if the infection occurred in the 3 months before.

If the patient had been infected between 3 and 6 months before, only one full dose was administered.

On September 9 th the Technical-Scientific Commission of AIFA (Italian Medicines Agency) recommended that individuals with certain immunocompromising conditions who received a twodose mRNA vaccine series receive a third dose as part of the primary vaccine series 23 . Starting on September 25 th 2021 we offered a third dose to patients on systemic antitumor treatment during COVID-19 vaccination or whose treatment has been completed in the last 6 months before vaccination. Safety assessments was performed by phone call 7 days after each dose for collecting data regarding solicited local and systemic adverse reactions. Solicited adverse events recorded were pain at injection site, sore arm, local erythema, fever, fatigue, headaches, chills, arthralgia, myalgia, diarrhoea, nausea, vomiting, flu-like symptoms, and lymphadenopathy. Unsolicited adverse events were collected within 28 days after each dose. Adverse events were graded according to a standard toxicity grading scale 24 . Electronic health records were accessed by the study investigators to review demographic information, disease history, treatment detail, and outcome events of participants patients'. Positive cases of SARS-CoV-2 infection were extracted from the COVID-19 integrated surveillance system of the National Institute of Health, on March 10 th 2022. The study was approved by the institutional review board.

J o u r n a l P r e -p r o o f

A logistic regression analysis predicting acute side effects after anti-COVID-19 vaccine (dependent variable; 0= No side effects; 1= Reported side-effects) was performed. We included as independent variables: type of cancer; no evidence of disease (NED) vs metastatic cancer; being under treatment vs follow-up; type of treatment; type of vaccine (the Moderna mRNA-1273 and the Pfizer and BioNTech BNT162b2 mRNA). The logistic regression analysis was performed for each dose (1 st dose; 2 nd dose; 3 rd dose) using a simple contrast for categorical variable to explore odd ratio (OR). Finally, a general linear model (GLM) with repeated measures was performed to explore how doses interact with significant predictors of linear regression analysis over time. The continuous score of side effects across the three doses was included as a unique factor comprising the within-subjects variables (side effect at 1 st dose, 2 nd dose, 3 rd dose, respectively). A repeated contrast was used for all the variable included in the model, using the first category as the reference one. In order to explore the comparison between the 1 st dose and the 3 rd dose a second GLM model was performed applying a simple contrast. All the analyses were conducted through SPSS version 25.

J o u r n a l P r e -p r o o f

The initial cohort included 911 patients, which were contacted via phone by the Hospital's care to schedule a vaccination appointment. 187 (20%) patients were already vaccinated belonging to other prioritized groups, 47 (5%) patients refused vaccination, mostly due to fear of side-effects, 48 (5%) patients could not be reached, and 11 (1%) patients had developed the disease less than 3 months before. The patients who refused vaccination on the first contact were called a second time after two weeks and 6 patient scheduled then a vaccination appointment, with a total refusal rate of 4.5%. As shown in Table 1 patients reporting more than one effect. Fever was reported in 95 (55%) patients, with a temperature ≥38 °C in 56% of them, lasting more than 24 hours in 66%. Pain at the injection site was reported in 58 patients (34%).

Descriptives of side effects across the three doses are reported in Table 2 . Logistic regression analysis reported mixed results, with limited variables or categories reporting a significant odd ratio as reported in Table 3 . The type of vaccine reported a significant value at first dose (OR= 0.12; CI 0.52, 0.26; p= 0.00) but not at second and third dose. Finally, we explored the interaction over time between severity of side-effects and sex, age (cut-off ≥75), NED vs metastatic cancer, type of cancer.

We did not found a significant effect both between and within subjects only for type of vaccine. The GLM model reported in Table 4 do not suggest an interaction over time, comparing Level 1 and 2, and Level 2 and 3. In order to compare Level 1 and 3 we also performed a GLM model using a simple contrast, but we did not find a significant interaction within subjects. Through the electronic medical 

The analysis we presented is a further real world evidence about tolerance and efficacy of the mRNA vaccines in cancer patients. Our results can be put beside to others similar published experiences about this topic. The sum of all these efforts leads in one way: vaccination must be strongly recommended in patients with cancer, as it is safe and will reduce the risk or severity of COVID-19 illness. Cancer patients, caregivers, healthcare professionals and, more broadly, the general population should comply with public health measures to better protect vulnerable people from COVID-19 infection.

MSP and SC conceived the study, and were responsible for data collection, data interpretation, data analysis along with GG, and they wrote the first draft of the manuscript; MP, VF, CG, were responsible for data collection;

MP, VF, CG, FM, FL, ASR, SS, CB, VB, IB, GDL, CF, RG, EM, SR, RT, FF, AB, and LF critically reviewed the manuscript and agreed with the decision to submit for publication.

We declare no competing interests. ** Other treatment within our cohort: bifosfonate (n = 6), chemio-immune therapy (n = 1), immune-target therapy (n = 1) Note. We included in the model as within-subjects factor the three continuos scores of severity of sideeffects across the three doses (Doses), and as between-subjects factor the type of vaccine (Moderna mRNA-1273 vs Pfizer BNT162b2 mRNA vaccine). Repeated contrast was used for all the variables. 

An interactive web-based dashboard to track COVID-19 in real time

Ministero della Salute; Presidenza del Consiglio dei Ministri; Istituto Superiore di Sanità

Vaccinazione anti-SARS-CoV-2/COVID-19. Piano Strategico

Priority covid-19 vaccination for patients with cancer while vaccine supply is limited

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Factors associated with COVID-19-related death using OpenSAFELY

High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Value of influenza vaccines in cancer patients during the coronavirus (COVID-19) pandemic: a cross-sectional study. Supportive Care in Cancer

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

COVID-19 vaccination in cancer patients: ESMO statements

VACCINAZIONE COVID-19 PER I PAZIENTI ONCOLOGICI. . 16 COVID-19 Vaccines & Patients with Cancer

Simple contrast method with first category (breast cancer) as reference. ** Cancer Type: breast cancer, gastroenteric cancer, melanoma, lung cancer, genitourinary cancer, gynecological cancer, skin cancer, prostatic cancer, glioblastoma, other type of cancer

We thank Giada Bazzani (supported by C.A.L.C.I.T. Valdarno Fiorentino) for direct technical assistance.J o u r n a l P r e -p r o o f

Severity of side effects Note. We report the proportion (%) of level of severity of side effects in the whole sample (A), and in the sub-samples of those vaccinated with either the Pfizer and BioNTech BNT162b2 mRNA (B) or the Moderna mRNA-1273 vaccines (C).

Highlights • COVID-19 vaccination is recommended in patients with cancer;• We observed a first dose-refusal rate of 4.5%;• No safety concerns have emerged in our cohort of patients;• After two-dose prime-boost vaccination 6 cases of COVID-19 infection were reported.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:J o u r n a l P r e -p r o o f